Bordetella Pertussis Toxin

CHEMBL6068349 Phase 4 Approuvé Vaccine component
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

The inactivated toxin produced by Bordetella pertussis bacteria and included in acellular pertussis vaccines to induce protective immunity against whooping cough. The toxin plays a central role in the disease process, and antibodies against it are important for protection. Inactivation ensures it is safe for use in vaccines while retaining immunogenicity.

Aires thérapeutiques

Mécanisme d'action

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The inactivated toxin produced by Bordetella pertussis bacteria and included in acellular pertussis vaccines to induce protective immunity against whooping cough. The toxin plays a central role in the disease process, and antibodies against it are important for protection. Inactivation ensures it is safe for use in vaccines while retaining immunogenicity.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Bordetella Pertussis Toxin is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068349. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.